1. Cancer Biology
  2. Developmental Biology

Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations

  1. Shaina N Porter
  2. Andrew S. Cluster
  3. Wei Yang
  4. Kelsey A Busken
  5. Riddhi M Patel
  6. Jiyeon A Ryoo
  7. Jeffrey A Magee  Is a corresponding author
  1. Washington University School of Medicine, United States
https://doi.org/10.7554/eLife.18882
Share this article
Cite this article
  1. Shaina N Porter
  2. Andrew S. Cluster
  3. Wei Yang
  4. Kelsey A Busken
  5. Riddhi M Patel
  6. Jiyeon A Ryoo
  7. Jeffrey A Magee
(2016)
Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations
eLife 5:e18882.
https://doi.org/10.7554/eLife.18882
  2. Download BibTeX
  3. Download .RIS

Abstract

The FLT3 Internal Tandem Duplication (FLT3ITD) mutation is common in adult acute myeloid leukemia (AML) but rare in early childhood AML. It is not clear why this difference occurs. Here we show that Flt3ITD and cooperating Flt3ITD/Runx1 mutations cause hematopoietic stem cell depletion and myeloid progenitor expansion during adult but not fetal stages of murine development. In adult progenitors, FLT3ITD simultaneously induces self-renewal and myeloid commitment programs via STAT5-dependent and STAT5-independent mechanisms, respectively. While FLT3ITD can activate STAT5 signal transduction prior to birth, this signaling does not alter gene expression until hematopoietic progenitors transition from fetal to adult transcriptional states. Cooperative interactions between Flt3ITD and Runx1 mutations are also blunted in fetal/neonatal progenitors. Fetal/neonatal progenitors may therefore be protected from leukemic transformation because they are not competent to express FLT3ITD target genes. Changes in the transcriptional states of developing hematopoietic progenitors may generally shape the mutation spectra of human leukemias.

Data availability

The following data sets were generated
The following previously published data sets were used
    1. Levine RL
    2. Shin A
    (2015) Tet2-/-Flt3ITD and WT stem and progenitor cells
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE57244).
    http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57244

Article and author information

Author details

  1. Shaina N Porter

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Andrew S. Cluster

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Wei Yang

    Department of Genetics, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Kelsey A Busken

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Riddhi M Patel

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Jiyeon A Ryoo

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Jeffrey A Magee

    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
    For correspondence
    Magee_J@kids.wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0766-4200

Funding

U.S. Department of Defense (CA130124)

  • Jeffrey A Magee

St. Baldrick's Foundation (Scholar Award)

  • Jeffrey A Magee

Hyundai Hope On Wheels (Hope Scholar)

  • Jeffrey A Magee

Gabrielle's Angel Foundation for Cancer Research (Medical Research Award)

  • Jeffrey A Magee

Children's Discovery Institute of Washington University and St. Louis Children's Hospital (Faculty Scholar Award)

  • Jeffrey A Magee

Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12-HD076224)

  • Jeffrey A Magee

Eunice Kennedy Shriver National Institute of Child Health and Human Development (5T32HD043010-12)

  • Andrew S. Cluster

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Scott A Armstrong, Harvard University, United States

Ethics

Animal experimentation: All mice were housed in the Department for Comparative Medicine at Washington University. All animals were handled and procedures were performed according to institutional animal care and use committee (IACUC) protocols 20130134 and 20160087. These protocols were approved by the Washington University Committees on the Use and Care of Animals.

Version history

  1. Received: June 16, 2016
  2. Accepted: November 21, 2016
  3. Accepted Manuscript published: November 23, 2016 (version 1)
  4. Version of Record published: December 12, 2016 (version 2)

Copyright

© 2016, Porter et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,846
    views
  • 397
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shaina N Porter
  2. Andrew S. Cluster
  3. Wei Yang
  4. Kelsey A Busken
  5. Riddhi M Patel
  6. Jiyeon A Ryoo
  7. Jeffrey A Magee
(2016)
Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations
eLife 5:e18882.
https://doi.org/10.7554/eLife.18882

Share this article

https://doi.org/10.7554/eLife.18882

Categories and tags

Research organism

Further reading

    1. Cancer Biology

    Overcoming the nutritional immunity by engineering iron-scavenging bacteria for cancer therapy

    Sin-Wei Huang, See-Khai Lim ... Kurt Yun Mou
    Research Article

    Certain bacteria demonstrate the ability to target and colonize the tumor microenvironment, a characteristic that positions them as innovative carriers for delivering various therapeutic agents in cancer therapy. Nevertheless, our understanding of how bacteria adapt their physiological condition to the tumor microenvironment remains elusive. In this work, we employed liquid chromatography-tandem mass spectrometry to examine the proteome of E. coli colonized in murine tumors. Compared to E. coli cultivated in the rich medium, we found that E. coli colonized in tumors notably upregulated the processes related to ferric ions, including the enterobactin biosynthesis and iron homeostasis. This finding indicated that the tumor is an iron-deficient environment to E. coli. We also found that the colonization of E. coli in the tumor led to an increased expression of lipocalin 2 (LCN2), a host protein that can sequester the enterobactin. We therefore engineered E. coli in order to evade the nutritional immunity provided by LCN2. By introducing the IroA cluster, the E. coli synthesizes the glycosylated enterobactin, which creates steric hindrance to avoid the LCN2 sequestration. The IroA-E. coli showed enhanced resistance to LCN2 and significantly improved the anti-tumor activity in mice. Moreover, the mice cured by the IroA-E. coli treatment became resistant to the tumor re-challenge, indicating the establishment of immunological memory. Overall, our study underscores the crucial role of bacteria’s ability to acquire ferric ions within the tumor microenvironment for effective cancer therapy.

    1. Cancer Biology
    2. Cell Biology

    Exosomes: How tumors escape the immune system

    Stefanie Schmieder
    Insight

    Mutations in the gene for β-catenin cause liver cancer cells to release fewer exosomes, which reduces the number of immune cells infiltrating the tumor.

    1. Cancer Biology
    2. Cell Biology

    mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3IBTK-mediated ubiquitination of eIF4A1 in cancer cells

    Dongyue Jiao, Huiru Sun ... Kun Gao
    Research Article

    Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.